Compounded semaglutide is not the same as Wegovy. While both are intended to contain semaglutide, they differ in their active ingredient form, manufacturing standards, regulatory status, and safety profile. These differences matter more than many people realize, and understanding them can help you make an informed choice about what you’re putting in your body.
The Active Ingredient Is Often Different
Wegovy uses the base form of semaglutide, the exact molecule that was tested in clinical trials and approved by the FDA. Many compounding pharmacies, however, use salt forms of semaglutide, typically semaglutide sodium or semaglutide acetate. These are chemically distinct active ingredients. The FDA has stated directly that it “does not have information on whether these salts have the same chemical and pharmacologic properties as the active ingredient in the approved drug.”
That distinction is important. A salt form of a drug can behave differently in the body: it may absorb at a different rate, have different potency, or interact differently with tissues at the injection site. With Wegovy, the base form of semaglutide was rigorously tested across large clinical trials that tracked its effects on weight, blood sugar, and cardiovascular health over years. The salt forms used in compounded versions have not gone through that process.
Compounded Versions Skip FDA Approval
Wegovy went through the full FDA approval process, which includes demonstrating safety and effectiveness through controlled clinical trials, validating manufacturing consistency, and meeting strict labeling requirements. Compounded semaglutide does not go through any of this. Compounded drugs are exempt from new drug approval requirements entirely.
Compounding pharmacies are legally permitted to prepare custom medications when a drug is in shortage or when a patient has a specific medical need that an approved product can’t meet (like an allergy to an inactive ingredient). As of early 2025, semaglutide no longer appears on the FDA’s drug shortage list, which significantly narrows the legal basis for compounding it.
Manufacturing Oversight Varies Widely
There are two categories of compounding pharmacies, and the quality gap between them is significant.
Traditional compounding pharmacies operate under Section 503A of federal law. They are licensed by their state, prepare medications based on individual prescriptions, and are exempt from the manufacturing standards (known as Current Good Manufacturing Practice) that govern pharmaceutical companies and larger facilities. The FDA inspects these pharmacies on a risk-based approach, often triggered by complaints rather than routine scheduling.
Outsourcing facilities, registered under Section 503B, face stricter requirements. They must follow Current Good Manufacturing Practice rules, and the FDA conducts routine surveillance inspections. However, even these facilities do not produce FDA-approved drugs. The FDA has encouraged patients who need compounded medications to seek out 503B outsourcing facilities when possible, since they are subject to greater oversight.
In practice, many people obtaining compounded semaglutide online or through telehealth platforms have no way of knowing which type of pharmacy filled their prescription, or what quality controls were applied during production.
Dosing Errors Are a Documented Risk
The FDA has received reports of serious adverse events tied to dosing errors with compounded semaglutide, some requiring hospitalization. The problems stem from the format itself. Compounded semaglutide typically comes in multi-dose vials that require you to draw up your own dose with a syringe. Wegovy, by contrast, comes in prefilled, single-dose pens that deliver a precise amount with each injection.
The most common error pattern is alarming: patients administered 5 to 20 times more semaglutide than intended. In several cases, patients were told to draw “5 units” from a vial using an insulin syringe but mistakenly drew 50 units instead. Healthcare providers also made calculation errors when converting between milligrams and units or milliliters. One provider prescribed 25 units when they meant 0.25 milligrams (which equals 5 units). Another prescribed 20 units instead of 2.
The resulting overdoses caused nausea, vomiting, severe abdominal pain, fainting, dehydration, acute pancreatitis, and gallstones. These are not minor inconveniences. Pancreatitis can be life-threatening, and gallstones may require surgery.
Added Ingredients With No Safety Data
Some compounders add extra ingredients to their semaglutide formulations, including vitamin B-12, vitamin B-6, L-carnitine, and a compound called NAD. These additions are often marketed as enhancing weight loss or energy levels. The safety and effectiveness of combining semaglutide with any of these ingredients has not been studied. You are essentially taking an untested drug cocktail, not a version of Wegovy.
This is a meaningful concern because semaglutide is a potent medication that affects multiple body systems, including appetite regulation, blood sugar control, and gastric emptying. Introducing additional active compounds without clinical data on their interactions creates unpredictable risks.
How to Verify a Compounding Pharmacy
If you are considering compounded semaglutide for any reason, the FDA recommends verifying the pharmacy through your state board of pharmacy’s license database. A legitimate compounding pharmacy should require a valid prescription from a licensed provider, have a physical address and phone number in the United States, and employ a licensed pharmacist who can answer questions about the product.
You can also check whether the pharmacy is registered as an outsourcing facility through the FDA’s website, which maintains a public list of 503B-registered facilities. Outsourcing facilities are held to higher manufacturing standards and are inspected more frequently. If a pharmacy is not listed in your state’s database, the FDA advises against using it.
The Bottom Line on Equivalence
Compounded semaglutide and Wegovy share a name, but they are not equivalent products. The active ingredient may be a different chemical form. The manufacturing process lacks the same quality controls. The delivery format introduces real dosing risks. And some formulations contain added ingredients never tested alongside semaglutide. Wegovy’s clinical trial data, which demonstrated specific weight loss outcomes and cardiovascular benefits, applies only to the exact formulation that was studied. It does not automatically extend to compounded versions, regardless of what the label says.